QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 08:06 UTC · Public disclosure record

65AVG SCORE

Andrew Garbarino

House Republican NY
Oversight and InvestigationsCapital MarketsHousing and Insurance

Andrew Garbarino has disclosed 16 stock transactions — 6 buys, 10 sells, each ranked by how much scrutiny it deserves and linked to its original House filing. A transparency record.

⚑
1 potential conflict of interest. Garbarino sits on committee(s) overseeing Defense, Finance, Insurance, Real Estate, and made 1 trade in those sectors (marked ⚑ below). This is a transparency signal, not an allegation of wrongdoing — such trades are often entirely legitimate.
16
Total trades
6
Buy
10
Sell
8
Avg. disclosure delay (days)
Estimated net worth 2024 financial disclosure · source ↗
Not estimable
Garbarino's disclosed liabilities ($300,002 – $600,000) exceed the disclosed assets ($90,016 – $353,000), so a net-worth figure isn't meaningful here. This is common and usually not a sign of real insolvency: a primary residence isn't a reportable asset, but a mortgage on it is a reportable liability, which can push disclosed net worth below zero on paper. We therefore show no % of NW tags for Garbarino's trades rather than a misleading number.

Track record Congressional Trading Performance

Two figures per horizon, both hypothetical and not investment advice: Member's own — what the trade returned if you'd bought when Garbarino did (not public yet, so not replicable); and If you'd followed — buying only after the disclosure went public, which is what a follower could actually do. The gap between them is the cost of the disclosure lag.

1 month
no price data
0 of 5 priced
3 months
no price data
0 of 5 priced
6 months
no price data
0 of 5 priced
1 year
no price data
0 of 5 priced
3 years
no price data
0 of 5 priced

We don't have price history covering Garbarino's trades — they may predate our price data or be on tickers we don't track — so hypothetical returns can't be computed here. The disclosures themselves are all listed below.

Where they trade Favorite Sectors

Distribution of this politician's trades across sectors (of trades with a known sector — bonds and funds are excluded).

Retail & Wholesale
1 (50%)
Finance
1 (50%)

Traded the same stocks, same time Co-Investors in Congress

Other members who traded the same tickers within 30 days of Garbarino's trades in them. A high overlap can reflect shared information, shared advisors, or simply popular stocks — it is not evidence of coordination.

PoliticianOverlapping tradesShared tickers
Blake Moore 2 BAC
August Lee Pfluger 1 BAC

Corporate insiders · SEC Form 4 Overlap with Insiders

On the trades where corporate insiders were also active, how often did Andrew Garbarino move the same way as the company's own officers and directors (within 60 days)? Co-occurrence only — context from public Form 4 filings, never proof of coordination, and tested honestly for whether it means anything.

17%
of checkable trades converged
avg 20% across all members
1
converged (of 6 checkable)
0
diverged

Andrew Garbarino's convergence rate of 17% is lower than the 20% average across all members. "Checkable" = trades on tickers where insiders were also trading, so convergence could even be measured.

Descriptive only — insider convergence is context from public SEC Form 4 filings, never proof of coordination or wrongdoing, and not investment advice.

13 trades Recent Transactions

Marker key: ⚑ potential conflict (a committee Garbarino sits on oversees that sector) · ◆ corporate-insider overlap from SEC Form 4 (convergence/divergence — context, not a signal) · % of NW trade size vs estimated net worth, 🔥 marking high/extreme conviction · OCR recovered from a scanned filing (verify against source) · ×N filings the same trade disclosed more than once (shown once). None is an allegation of wrongdoing.

TickerCompanyTypeDateFiledLagPrice move
in that
window
AmountScoreSource
GAP Gap Inc. SELL ◆ insider convergence 2025-08-21 2025-08-21 0 days — $1K–$15K 84.6 ↗ filing
ORMP Oramed Pharmaceuticals Inc. SELL 2022-01-14 2022-01-14 0 days — $1K–$15K 29.4 ↗ filing
TELL Tellurian BUY 2022-01-14 2022-01-14 0 days — $1K–$15K 50.2 ↗ filing
GPS Gap BUY 2021-10-01 2021-10-04 3 days — $1K–$15K 84.6 ↗ filing
OSW Onespaworld Holdings Ltd. SELL 2021-10-01 2021-10-04 3 days — $1K–$15K 50.2 ↗ filing
ORMP Oramed Pharmaceuticals Inc. SELL 2021-10-01 2021-10-04 3 days — $1K–$15K 50.2 ↗ filing
TELL Tellurian BUY 2021-10-01 2021-10-04 3 days — $1K–$15K 84.6 ↗ filing
— Vmccx BUY 2021-06-07 2021-06-26 19 days — $1K–$15K 50.2 ↗ filing
— Capital World Grow And Income SELL 2021-06-03 2021-06-26 ×4 filings 23 days — $1K–$15K 50.2 ↗ 1 ↗ 2 ↗ 3 ↗ 4
⚑ BAC Bank Of America Corp. SELL 2021-04-23 2021-04-26 3 days — $1K–$15K 99.5 ↗ filing
GSS Golden Star Resources SELL 2021-04-23 2021-04-26 3 days — $1K–$15K 84.6 ↗ filing
OSW Onespaworld Holdings Ltd. BUY 2021-04-23 2021-04-26 3 days — $1K–$15K 84.6 ↗ filing
ORMP Oramed Pharmaceuticals Inc. BUY 2021-04-23 2021-04-26 3 days — $1K–$15K 84.6 ↗ filing

A trade can appear in more than one filing (e.g. a periodic transaction report and a later annual disclosure). Those are shown once here — marked ×N filings, with a link to each — so the table reflects distinct trades, while the 16 total above counts every disclosed line.

FAQ Common questions

How many stock trades has Andrew Garbarino disclosed?

16 disclosed stock transactions — 6 buys and 10 sells — all from official House financial disclosures.

Is this insider trading?

No. QuantCapitol surfaces the timing and context of publicly disclosed trades for transparency. A trade near related legislation is a coincidence we flag — never an accusation of wrongdoing.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.